BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31863004)

  • 1. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog pathway permissive conditions allow generation of immortal cell lines from granule cells derived from cancerous and non-cancerous cerebellum.
    Heil C
    Open Biol; 2019 Jan; 9(1):180145. PubMed ID: 30958113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma.
    Coon V; Laukert T; Pedone CA; Laterra J; Kim KJ; Fults DW
    Mol Cancer Ther; 2010 Sep; 9(9):2627-36. PubMed ID: 20807782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth.
    Binning MJ; Niazi T; Pedone CA; Lal B; Eberhart CG; Kim KJ; Laterra J; Fults DW
    Cancer Res; 2008 Oct; 68(19):7838-45. PubMed ID: 18829539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
    Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
    Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
    Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
    Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.
    Zhang L; He X; Liu X; Zhang F; Huang LF; Potter AS; Xu L; Zhou W; Zheng T; Luo Z; Berry KP; Pribnow A; Smith SM; Fuller C; Jones BV; Fouladi M; Drissi R; Yang ZJ; Gustafson WC; Remke M; Pomeroy SL; Girard EJ; Olson JM; Morrissy AS; Vladoiu MC; Zhang J; Tian W; Xin M; Taylor MD; Potter SS; Roussel MF; Weiss WA; Lu QR
    Cancer Cell; 2019 Sep; 36(3):302-318.e7. PubMed ID: 31474569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors.
    Zhao X; Ponomaryov T; Ornell KJ; Zhou P; Dabral SK; Pak E; Li W; Atwood SX; Whitson RJ; Chang AL; Li J; Oro AE; Chan JA; Kelleher JF; Segal RA
    Cancer Res; 2015 Sep; 75(17):3623-35. PubMed ID: 26130651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation.
    Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells.
    Dey A; Robitaille M; Remke M; Maier C; Malhotra A; Gregorieff A; Wrana JL; Taylor MD; Angers S; Kenney AM
    Oncogene; 2016 Aug; 35(32):4256-68. PubMed ID: 26725322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
    Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.